Seventeen health systems are investing in a genomic database that could significantly drive down clinical costs. Truveta, a Washington-based software company, unveiled the Truveta Genome Project on ...

Thus far 2025 has come roaring in as far as large rounds go. Last week more than a dozen companies raised $100 million or ...

The Fortune 500 pharma giant will sequence the exomes of 10 million people, with the goal of developing new therapies and ...

It was an extremely busy week in the biotech sector, with several companies making important presentations at the J.P. Morgan ...

US health systems and Regeneron Genetics Center launch the Truveta Genome Project, a $320M initiative to sequence up to 10M ...

The health systems, Illumina, and Regeneron have invested $320M in what Truveta calls the largest and most diverse database ...

In this article, we are going to take a look at where Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) stands against the other stocks. In one of his latest appearances on CNBC’s Squawk on the ...

Several large drugmakers will ask the Trump administration to pause Medicare drug-price negotiations, even as Biden-appointed officials prepare a new list of medicines that should be targeted, ...

Also in the news: Neuralink, J&J, Bayer, Nvidia, Amazon Web Services, and more. Stat: Truveta Joins Drugmakers To Launch Massive Genomic Database Health data company Truveta said Monday it’s ...

After Regeneron Chief Scientific Officer George Yancopoulos, M.D., Ph.D., spent more than 25 minutes waxing about the company’s deep pipeline Monday at the J.P. Morgan Healthcare Conference ...

New York: Medical data research company Truveta said on Monday that Regeneron Pharmaceuticals , Illumina and 17 U.S. health systems will take a $320 million stake in the company as part of a deal ...

Regeneron Pharmaceuticals, Inc. REGN provided business and pipeline updates at the 43rd Annual J.P. Morgan Healthcare Conference. Shares of the company moved up in pre-market trading on Jan. 14.